WEBINAR SERIES: Modern medicines series SGLT2 Inhibitors: What we need to know

About the series

Over the first 3 programmes in this series, Professor Cliff Bailey and colleagues provided concise evidence-based guidance to contemporary medications and their application in daily care with the aim of assessing the clinical evidence and opportunities offered by sodium-glucose co-transporter-2 (SGLT2) inhibitors in the management of type 2 diabetes and its cardio-renal complications. These can now be viewed on our on-demand page, see below.

Still to come in the series…

SGLT2 inhibitors: All you need to know in 30 minutes

Tuesday 14^th December, 19:00 hours

Presenters: Professor Cliff Bailey & Dr Martin Hadley-Brown

A quick ‘bite-size’ update on SGLT2 Inhibitors from the 2021 major congresses. Prof Bailey will provide a quick revision of where we are before updating us on the latest CVD and renal developments while Dr Martin Hadley-Brown will join for the interactive audience discussion to answer questions from a primary care practicality point of view.

The webinar will include:

• 30 minute ‘bite-size’ session
• SGLT2 Inhibitors and CV disease: Where we are now (Prof. Bailey)
• SGLT2 Inhibitors and renal disease: Where we are now (Prof. Bailey)
• 15 minute Q&A and audience discussion (Prof. Bailey & Dr Hadley-Brown)

To finish the series in 2022…

SGLT2 inhibitors: Translating the Guidelines

(Date tbc) February, 19:00 hours

Presenters: Professor Cliff Bailey & Dr Martin Hadley-Brown tbc

A quick ‘bite-size’ translation of the new Guidelines with focus on the use of SGLT2 Inhibitors, covering the latest ADA/EASD consensus plus the revision of the Primary Care Europe Diabetes Guidelines. Prof Bailey will provide a quick revision of where SGLT2’s sit within the current guidance before Dr Hadley-Brown translates what is new and how this impacts primary care. There will then be an interactive audience discussion to answer questions from primary care.

The webinar will include:

• 30 minute ‘bite-size’ session
• SGLT2 Inhibitors: Current guidance (Prof. Bailey)
• SGLT2 Inhibitors: What is new for primary care (Dr Hadley-Brown)
• 15 minute Q&A and Audience discussion (Prof. Bailey & Dr Hadley-Brown)

We will notify you in due course when registration for the February date opens.

Your programme presenters

	Professor Cliff Bailey Emeritus Professor of Clinical Science, Aston University, Birmingham		Professor Vinod Patel Professor, Diabetes and Clinical Skills, Warwick Medical School. Honorary Consultant in Endocrinology and Diabetes, George Eliot Hospital, Nuneaton
	Dr Martin Hadley-Brown FRCGP, Hughes Hall, University of Cambridge		Dr Pam Brown GP, SA1 Medical Practice, Swansea

You can now watch Programmes 1, 2 & 3 on-demand. If you cannot attend any of the live broadcasts, the webinars will be available on-demand 24 hours after the event.

Included in each programme:

• A one hour webinar including a live Q&A discussion
• Downloadable slides to print off and keep
• A downloadable factsheet summarising the guidance
• A case study based CPD learning module with certificate upon completion

Programme 1 – Understanding SGLT2 inhibition Tuesday 9th February, 19.00 Speaker: Professor Cliff Bailey Type 2 diabetes and SGLT2 inhibitors in context Type 2 diabetes as a metabolic and cardio-renal disease Different glucose-lowering therapies The SGLT2 inhibitor class Mechanism of SGLT2 inhibition Speaker: Professor Vinod Patel Managing glycaemic control and body weight Glucose control and weight control in RCTs Real world evidence of efficacy  Tolerability and safety profiles Positioning in treatment algorithms for type 2 diabetes Click below to watch the webinar on-demand. Watch on-demand now Request a password This webinar is password protected, you will have received the password in the invitation email. If you don’t have a password please feel free to email us at: admin@issuesandanswers.org.

Programme 2 – SGLT2 inhibitors and the heart Tuesday 23rd February, 19.00 Speaker: Professor Cliff Bailey Effects of SGLT2 inhibitors on cardiovascular function Cardiovascular disease in type 2 diabetes SGLT2 inhibitors lower blood pressure SGLT2 inhibitors reduced heart failure risk Mechanisms of SGLT2 inhibitors on heart and circulation Speaker: Dr Martin Hadley-Brown Role of SGLT2 inhibitors in the management of CV disease Improve BP control independently of other antihypertensives Reduce risk of new onset or worsening heart failure  May benefit atherosclerotic cardiovascular disease Positioned in algorithms for type 2 diabetes by CV effects Click below to watch the webinar on-demand. Watch on-demand now Request a password This webinar is password protected, you will have received the password in the invitation email. If you don’t have a password please feel free to email us at: admin@issuesandanswers.org.

Programme 3 – SGLT2 inhibitors and the kidney Tuesday 9th March, 19.00 Speaker: Professor Cliff Bailey Reno-protective effects of SGLT2 inhibitors Kidney disease in type 2 diabetes SGLT2 inhibitors and glomerular filtration rate SGLT2 inhibitors reduced albuminuria Reno-protective mechanisms of SGLT2 inhibitors Speaker: Dr Pam Brown SGLT2 inhibitors in the management diabetic kidney disease Slow decline in glomerular filtration rate Reduce albuminuria  Delay progression of CKD without diabetes Value in prevention and treatment of diabetic kidney disease Click below to watch the webinar on-demand. Watch on-demand now Request a password This webinar is password protected, you will have received the password in the invitation email. If you don’t have a password please feel free to email us at: admin@issuesandanswers.org.